Company intelligence / Profile preview
Akamis Bio
Cambridge, Massachusetts, United Statesakamisbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Akamis Bio has treated more than 200 patients across monotherapy and combination settings with checkpoint inhibitors. Their T-SIGn therapeutics have demonstrated a consistent safety and tolerability profile, with promising preliminary evidence of clinical activity. Their lead program NG-350A has shown proof-of-mechanism with evidence of tumor-selective delivery, replication, and transgene expression.
- Therapeutic areas
- Oncology
- Modalities
- Tumor gene therapyViral vector-based therapies
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Beyond the preview
Go deeper on Akamis Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Akamis Bio.